NIH Releases New Statement on Bebtelovimab
December 07, 2022
The prevalence of SARS-CoV-2 Omicron subvariants that are anticipated to be resistant to bebtelovimab has been rapidly increasing in the United States. On November 30, 2022, the Food and Drug Administration announced that bebtelovimab is no longer authorized for the treatment of COVID-19 in any U.S. region.
Therefore, the COVID-19 Treatment Guidelines Panel (the Panel) now recommends against the use of bebtelovimab for the treatment of nonhospitalized patients with COVID-19 who are at high risk of progressing to severe COVID-19. As the antiviral drugs ritonavir-boosted nirmatrelvir (Paxlovid), remdesivir, and molnupiravir are expected to be active against the currently circulating Omicron subvariants, the Panel continues to recommend these drugs for the treatment of these patients.
For more information, please read the full statement on the COVID-19 Treatment Guidelines website.